Navigation Links
Optimer Pharmaceuticals' Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
Date:8/19/2010

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the European Medicines Agency (EMA) has accepted for review Optimer's Marketing Authorization Application (MAA) for fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI in the European Union (EU).  Optimer announced the submission of its MAA for fidaxomicin to the EMA on August 2, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"An independent survey recently conducted by Decision Resources indicates that CDI is on the rise and that nearly 70% of surveyed infectious disease specialists and internists would use fidaxomicin in first- and second-line treatment of CDI, if approved," said Pedro Lichtinger, President and CEO of Optimer. "We believe the potential demand for a narrow spectrum antibiotic with lower recurrence rates for the treatment of CDI is significant. The acceptance for review of the fidaxomicin marketing application by the EMA is an important step in bringing this much needed therapy to Europe, where treatment options are limited.  With the validation of this MAA, we believe we have significantly improved the risk profile of our European program that when combined with our growing excitement and understanding of CDI incidence, access and prescribing intentions across the region, present an enhanced value proposition for fidaxomicin."  

Given these developments, the Company is increasing its focus on its European partnering process for fidaxomicin. J.P. Morgan has been engaged to advise and assist Optime
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... release its second quarter 2014 financial results for the period ... market close. PDL,s management will host a conference call and ... the financial results.  A slide presentation relating to the call ... website. Conference Call Details To access the ...
(Date:7/28/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Results and Highlights Conference CallWhen:Monday, August 4 at 10:30 ... on the Internet. Simply log onto our website listed ... live event, a replay of the webcast will be ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting ...
(Date:7/28/2014)...  ProteinSimple announced today that it has launched a ... allows users to detect all proteins separated in the ... can analyze proteins without the need for an antibody.  ... analysis as we know it today. First, the Simple Western ... messy gels, no transfer tanks, no blots, no imaging ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2ProteinSimple Says "Never Run a Gel Again!" 2
... /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ... traded biopharmaceutical company developing human vaccines for diseases ... infectious agents, announced today that Chuck Panozzo, founder ... joined the GeoVax Labs awareness campaign as an ...
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting ... hospital days during the first year after treatment compared ...
Cached Medicine Technology:Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5
(Date:7/28/2014)... (PRWEB) July 28, 2014 Mahendra Trivedi, ... hosted the Trivedi Online Workshop ‘Consciousness is Power’ on ... (EST). During this workshop, participants from all over the ... of making a deeper connection to their inner guidance ... participants explored the various advantages of raising consciousness and ...
(Date:7/28/2014)... Scientists in Japan have completed initial tests ... for the asbestos cancer mesothelioma. Surviving Mesothelioma has just ... here to read it now. , Researchers in ... Graduate School of Medicine say a new test for ... the old test. , “Particularly for the epithelioid ...
(Date:7/28/2014)... Neenah, Wisconsin (PRWEB) July 28, 2014 ... management business process outsourcing (BPO) for Fortune 500 brands, ... 2,500 jobs across its locations in Wisconsin, California, Florida ... will be based at its Neenah campus. , A ... clients, which have seasonal ramp-ups that require additional staffing ...
(Date:7/28/2014)... Community Health Center of Snohomish County (CHC), a non-profit ... released an article designed to educate patients about the ... 1983, the health center has a strong focus on ... barriers to obtaining high quality yet affordable healthcare services. ... click here: http://www.chcsno.org/locations.ashx?p=1099 , The article begins ...
(Date:7/28/2014)... The research found that most of ... best, with each subsequent bite being less satisfying than ... serve to sabotage the meal. , "People have ... realizing the effect," Baba Shiv, the study's author, said ... if we needed one. You actually take more pleasure ...
Breaking Medicine News(10 mins):Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 3Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3Health News:Large Portions Can Decrease Food Enjoyment, SlimPlate Weight Loss System Puts Focus On Portion Control 2Health News:Large Portions Can Decrease Food Enjoyment, SlimPlate Weight Loss System Puts Focus On Portion Control 3
... overall incidence of cancer and death due to cancer dropped ... United States, according to a report published in the November ... Cancer Institute . , Each year the American Cancer Society, ... Institute, and the North American Association of Central Cancer Registries ...
... Outbreak in WestMiddlesexAreaSchool District Sickens 32 , ... to a pertussis outbreak in the West Middlesex Area School ... Luther Low Elementary School and West Middlesex Junior/Senior High School ... , The tetanus/diphtheria/pertussis vaccine was given ...
... expert says , , TUESDAY, Nov. 25 (HealthDay News) -- ... tiny pumps implanted in people with failing hearts -- ... , However, the finding should not affect current medical ... replaced by second- and third-generation VADS that are far ...
... Health Issues , , WASHINGTON, ... will present its Conference on Health Disparities on January 30-31, ... This conference is part of the NABJ Media Institute,s professional ... number of health disparities in the black community and to ...
... and CEO, Melissa Murer Corrigan, RPh, has received the 2008 ... the National Organization for Competency Assurance (NOCA). The award recognizes ... programs or practices for the field of certification and licensure. ... ...
... Nov. 25 Stop and think. That is what,Las Vegas-based ... are asking Las Vegas to do this World AIDS Day. ... the day with a,fundraising dinner to re-launch a new educational ... For the past three ...
Cached Medicine News:Health News:Limited Value Found for First-Generation Heart Pumps 2Health News:Limited Value Found for First-Generation Heart Pumps 3Health News:Black Journalists to Host Conference on Health Disparities 2Health News:Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award 2Health News:Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award 3Health News:Las Vegas Charities Mark World AIDS Day by Asking Residents to 'THINK' 2
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
Toothed Pituitary Rongeurs, 12 300 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: